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During assembly of the HIV-1 virions, cellular tRNA3
Lys is packaged into the virion particles and is utilized as a primer for
the initiation of reverse transcription. The 3-terminal 18 nucleotides of the cellular tRNA3
Lys are complementary to nucleotides
183–201 of the viral RNA genome, referred to as the primer binding sequence (PBS). Additional sequences (A-Loop) upstream
of the PBS are essential for tRNA primer selection. We report here that a PNA targeted to PBS and A-Loop sequence (PNAPBS)
exhibits high specificity for its target sequence and prevents tRNA3
Lys priming on the viral genome. We also demonstrate that
PNAPBS is able to invade the duplex region of the tRNA3
Lys–viral RNA complex and destabilize the priming process, thereby
inhibiting the in vitro initiation of reverse transcription. The endogenously packaged tRNA3
Lys bound to the PBS region of the
viral RNA genome in the HIV-1 virion is efficiently competed out by PNAPBS, resulting in near complete inhibition of initiation
of endogenous reverse transcription. Examination of the effect of PNAPBS on HIV-1 production in CEM cells infected with
pseudotyped HIV-1 virions carrying luciferase reporter exhibited dramatic reduction of HIV-1 replication by nearly 99%.INTRODUCTION
Replication of human immunodeficiency virus type 1
(HIV-1) occurs through a multistep reverse transcription
process, in which the single-stranded viral RNA genome
is converted into double-stranded proviral DNA interme-
diate prior to integration into the host chromosome. The
process of reverse transcription is carried out by the
virally encoded reverse transcriptase, which utilizes the
cellular tRNA3
Lys bound to the primer-binding site (PBS)
near the 5 nontranslated region of the viral RNA genome
as primer. Among the currently utilized therapies for
AIDS are inhibitors which block the process of reverse
transcription of viral RNA into double-stranded DNA (Lar-
der, 1993; Wei et al., 1995; Ho et al., 1995). However, the
rapid emergence of drug-resistant strains has consider-
ably overshadowed the benefits of anti-HIV-1 drugs. Se-
lection of the dominant, preexisting drug-resistant vari-
ants and the abundance of latently infected cells (which
possess the integrated proviral DNA) are the potential
barriers encountered against effective drug therapy (Ho
et al., 1995; Wei et al., 1995; Embretson et al., 1993).
In recent years, it has become apparent that identifi-
cation of novel viral targets and antiviral agents are
needed to empower anti-HIV-1 therapeutic strategies.
The unique 5 (U5) nontranslated region (1–333 nucleo-297tides) of the HIV-1 genome comprises a number of reg-
ulatory regions essential for viral replication which may
be potential targets for drug intervention. These critical
domains are as follows: (i) the primer-binding site (nu-
cleotides 183–201), essential for tRNA3
Lys-primed initiation
of reverse transcription (Muesing et al., 1987; Ratner et
al., 1985; Sherman et al., 1992); (ii) the A-loop region
(nucleotides 168–173), located upstream of the PBS and
essential for the selection and interaction of tRNA3
Lys
primer (Wakefield et al., 1996; Li et al., 1997); (iii) the LTR
sequences at the 5 and 3 ends, essential for viral
transcription and integration (Vink et al., 1991); and (iv)
the trans-activation response element (TAR), essential
for viral gene expression via transcriptional activation
(Cullen and Green, 1990) and probably having some
additional role in the initiation of reverse transcription
(Harrich et al., 1997).
Several approaches have been used to arrest retrovi-
ral replication or regulate its gene expression. Prominent
among these have been antisense strategies to block
various viral replication steps, in which nucleic acids
may play an important role (Helene, 1997; Leeds et al.,
1997). One promising approach has been the use of
peptide nucleic acid (PNA) oligomers that bind selec-
tively to complementary DNA or RNA sequences and
inhibit translation and replication. PNA are nucleic acid
analogues containing polynucleobase linked with pep-Analysis of the mechanism of PNAPBS-mediated inhibition in
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earlier shown that a PNA targeted to the PBS region of
the viral genome blocks reverse transcription of U5 PBS
HIV-1 RNA primed with the DNA primer or synthetic
tRNA3
Lys (Lee et al., 1997). We have also demonstrated
that PNA targeted to the TAR sequences of viral RNA
genome is able to prevent Tat–TAR interaction by effi-
cient sequestration of the TAR and blocking the Tat-
mediated transactivation of the HIV-1 LTR transcription
(Mayhood et al., 2000).
In this article, we report that a 16-mer anti-PBS PNA
(PNAPBS), targeting five nucleotides of the PBS se-
quences and 11 nucleotides upstream of PBS in the 5
nontranslated region of the viral genome, can specifically
sequester its target sequence and prevent tRNA3
Lys prim-
ing on the viral genome. Further, PNAPBS is able to com-
pete out the packaged tRNA3
Lys, thereby destabilizing it
and inhibiting the endogenous reverse-transcription pro-
cess in the virions. PNAPBS also dramatically inhibits
HIV-1 replication in CEM cells infected with pseudotyped
HIV-1 virions by predominantly interfering with the re-
verse-transcription process. Scrambled PNA has no in-
fluence either on the reverse transcription process or on
the replication of the HIV-1-infected cells, thus indicating
the specificity of PNAPBS. These findings suggest the
potential of PNAPBS in blocking the process of HIV-1
replication.
RESULTS
Binding specificity of PNAPBS to U5 PBS HIV-1 RNA
We used the labeled U5 PBS HIV-1 RNA to determine
the binding specificity of PNAPBS targeted to the PBS
region of HIV-1 genome. The sequence of U5 PBS RNA
as well as PNAPBS and scrambled PNA are shown in Fig.
1. The PNAPBS and scrambled PNA contain 16 and 17
bases, respectively, linked with polyamide backbone.
The sequence of PNAPBS was designed such that five of
its N-terminal bases are complementary to the 3 termi-
nal PBS bases spanning nucleotides 183–187, while the
remaining C-terminal bases are complementary to the
sequences upstream of the PBS (172–182 nucleotides).
To ascertain the ability of PNAPBS to interact with PBS
sequences on the viral RNA, gel-retardation assays were
performed with 32P-labeled 200-base-long U5 PBS RNA
and varying concentrations of PNAPBS or scrambled PNA
(Fig. 2). Titration of PNAPBS with U5 PBS RNA at molar
ratios of PNAPBS to U5 PBS RNA less than 1 resulted in a
stoichiometric band shift of the labeled U5 PBS RNA (Fig.
2, lanes 2–10). As seen in the figure, at molar ratios of 0.1,
0.3, 0.5, 0.6, 0.7, 0.8, and 0.9 of PNAPBS to labeled U5 PBS
RNA, the extent of band shift corresponded to 12, 27, 52,
58, 67, 72, and 87%, respectively. A complete shift in the
mobility was achieved at equimolar or molar excess of
PNAPBS to U5 PBS RNA (lanes 9 and 10). A similar titration
was carried out in the presence of scrambled PNA.
Scrambled PNA at fivefold molar excess of U5 PBS RNA
exhibited no shift in the mobility of the labeled U5 PBS
RNA (Fig. 2, lanes 11–15). This indicates that the gradient
of band shift observed as a function of PNAPBS concen-
tration is due to sequence-specific interaction between
PNAPBS and U5 PBS RNA.
Disruption of binding interaction between tRNA3
Lys and
U5 PBS RNA by PNAPBS
To determine the effect of PNAPBS on the formation
(tRNA3
Lys-viral RNA) complex as well as on (HIV-1 RT-
tRNA3
Lys) complex, we carried out gel-retardation analysis
(Fig. 3A). Incubation of U5 PBS RNA with the labeled
tRNA3
Lys resulted in the formation of a distinct complex
between the tRNA3
Lys and viral RNA as discerned by a
shift in their mobility on a non-denaturing gel (lane 1).
Incubation of this preformed (tRNA3
Lys–viral RNA) complex
with increasing concentrations of PNAPBS resulted in the
disruption of this complex in a concentration-dependent
manner as noted by a significant decrease in the inten-
sity of the slower migrating complex (lanes 2–4). This
suggests that the chargeless PNAPBS is able to invade
the tRNA3
Lys-primed duplex region of the viral RNA result-
ing in the tRNA3
Lys displacement. This complex formation
was completely blocked when PNAPBS was incubated
with the U5 PBS RNA prior to its priming with the tRNA3
Lys,
suggesting that PNAPBS once bound to its target se-
quence prevents tRNA3
Lys priming/binding (lanes 6–8).
Interestingly, an oligonucleotide having identical se-
quence as PNAPBS was unable to disrupt the preformed
complex of (tRNA3
Lys-U5 PBS RNA), although it was able to
block tRNA3
Lys priming when preincubated with the U5
PBS RNA prior to priming with tRNA3
Lys (results not
shown). Incubation of the tRNA3
Lys with HIV-1 RT, in the
absence of PNAPBS (lane 9) or in its presence (lane 10)
resulted in complete supershift in the mobility of the
HIV-1 RT-tRNA3
Lys-binary complex, thus suggesting that
PNAPBS has no influence on the binding of tRNA3
Lys with
the viral enzyme.
A similar experiment was carried out in the presence
of scrambled PNA (Fig. 3B). As shown in the figure,
scrambled PNA neither disrupted the preformed com-
plex of tRNA3
Lys-U5 PBS RNA (lanes 2–4) nor prevented
the formation of this complex when preincubated with
the U5 PBS RNA prior to its priming with tRNA3
Lys (lanes
6–8). Similar to PNAPBS, scrambled PNA did not affect
tRNA3
Lys binding to HIV-1 RT (lanes 9 and 10). These
experiments clearly indicate the potential of PNAPBS in
efficiently disrupting the (viral RNA–tRNA3
Lys) complex.
Blockage of reverse transcription as a function of
PNAPBS concentration
Since initiation of HIV-1 reverse transcription requires
the priming of HIV-1 genome with the natural tRNA3
Lys
primer, we examined the influence of PNAPBS on the
initiation process of reverse transcription. For this pur-
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pose, U5 PBS RNA primed with the natural tRNA3
Lys was
incubated at varying molar ratios of PNAPBS or scrambled
PNA to TP. Reverse transcription was initiated by HIV-1
RT in the presence of labeled dNTPs. The results are
shown in Fig. 4A. Reverse transcription of tRNA3
Lys-primed
reaction resulted in the synthesis of ()-strand strong
stop DNA (sssDNA) of expected length (257 nucleotide)
(Fig. 4A, lane 1). Incubation of the template primer with
PNAPBS significantly decreased the synthesis of sssDNA
as a function of PNAPBS concentrations (lanes 2–7).
PNAPBS invaded the duplex region of the template primer
and displaced tRNA3
Lys from the viral genome, thereby
inhibiting initiation as well as elongation of reverse tran-
scription at all concentrations. Scrambled PNA had no
influence on the reverse transcription under identical
conditions (lanes 8–10).
In another set of experiments, the PBS sequence of U5
PBS RNA was blocked by preincubating with PNAPBS and
then allowed to interact with tRNA3
Lys prior to initiation of
reverse transcription. The results shown in Fig. 4B
FIG. 1. Sequences of PNAPBS, PNASCB, and the U5 PBS HIV-1 RNA. The sequence of U5 PBS HIV-1 RNA genome encompassing the TAR (R), 5 UTR,
and PBS regions is as shown. The sequence of PNAPBS and PNASCB is as shown in the box. The 3 terminal 18 nucleotides of tRNA3
Lys which primes
to the PBS region are as indicated. The sequences within the PBS and 5 UTR interacting with the PNAPBS are underlined.
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clearly demonstrate the efficacy of PNAPBS in preventing
the sssDNA synthesis on tRNA3
Lys primer (lanes 2–7). At
as low as 2.5 molar ratio of PNAPBS to TP, near complete
absence of ssDNA product was noted (lane 2). The
nonspecific scrambled PNA exhibited no effect on re-
verse transcription under identical conditions (Fig. 4B,
lanes 8–10). These results suggest that PNAPBS once
bound to its target sequence cannot be competed out by
tRNA3
Lys.
PNAPBS mediated inhibition of the endogenous
reverse transcription in the disrupted HIV-1 virions
Since PNAPBS significantly inhibited the in vitro initia-
tion and subsequent extension of tRNA3
Lys-primed reverse
transcription, it was of interest to see whether such
inhibition could also be seen with the isolated HIV-1
virion particles. We therefore examined the efficacy of
PNAPBS in invading the tRNA3
Lys-primed duplex region in
the disrupted HIV-1 virions and blocking the process of
reverse transcription. Aliquots of disrupted virions were
incubated in the presence of varying concentrations of
PNAPBS or scrambled PNA for a stated time. Reverse
transcription was then catalyzed by the endogenous
HIV-1 RT present in the disrupted virions, by supplement-
ing the reaction mixture with a cocktail of dNTPs includ-
ing labeled dCTP. The result of this analysis is presented
in Fig. 5A. In the absence of PNAPBS (lane C), substantial
amounts of reverse-transcription products, smaller as
well as larger than the expected size of () sssDNA (257
nucleotide), were obtained. The presence of larger prod-
ucts may be attributed to the efficient strand transfer
reaction, whereas incomplete () sssDNA products may
have accumulated due to their inability to participate in
the strand transfer reaction. Incubation of the disrupted
virions with PNAPBS significantly decreased the reverse-
transcription products. This decrease corresponded to
both the initiation and the subsequent elongation prod-
ucts and correlated with the concentration of PNAPBS
(lanes 1–8). At 25 nM PNAPBS concentration, approxi-
mately 30% inhibition of reverse transcription was ob-
tained (lane 2), which gradually increased to 95% inhibi-
tion at 750 nM PNAPBS concentration (lane 6). In contrast,
FIG. 2. Binding specificity of PNAPBS to its target sequence on the HIV-1 genomic RNA. Varying molar ratios of PNAPBS or PNASCB were incubated with the
labeled U5 PBS RNA transcript (5  103 Cerenkov cpm), and their binding affinity and specificity was assessed by gel shift analysis. Lanes 1 through 10
represent molar ratios of PNAPBS to U5 PBS RNA of 0, 0.1, 0.3, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, and 5.0, respectively. Lanes 11–15 represent gel shift with PNASCB at
molar ratios of PNASCB to U5 PBS RNA of 0.1, 0.5, 1.0, 2.5, and 5.0, respectively. The labeled U5 PBS RNA band was quantified on phosphorImager using
Image-Quant software (Molecular Dynamics). The percentage of U5 PBS RNA retarded due to PNA binding is as indicated under each lane.
FIG. 3. Effect of PNAPBS or PNASCB on the formation of (tRNA3
Lys-U5
PBS RNA) complex. U5 PBS RNA preprimed with the labeled tRNA3
Lys
was incubated in the presence or absence of PNAPBS (A) or PNASCB (B)
under conditions as stated for the individual lanes. The complex formed
was resolved on a native gel and analyzed on a phosphorImager.
Lanes 1–4, incubation of the preformed complex in the presence of
PNAPBS or PNASCB at molar ratios of PNA to U5 PBS RNA of 0.0, 1.0, 2.5,
and 5.0, respectively. Lane 5, 32P-labeled tRNA3
Lys alone; lanes 6–8, U5
PBS RNA was preincubated with PNAPBS or PNASCB at molar ratios of
PNA to U5 PBS RNA of 1.0, 2.5, and 5.0, respectively, followed by further
incubation with labeled tRNA3
Lys; Lanes 9 and 10, represent formation of
(tRNA3
Lys-HIV-1 RT) complex in the absence or presence of 1 M PNAPBS
or PNASCB, respectively. The positions of free tRNA3
Lys, (U5 PBS RNA-
tRNA3
Lys) complex, and (tRNA3
Lys-HIV-1 RT) complex are as indicated.
300 KAUSHIK AND PANDEY
incubation of the disrupted virions with scrambled PNA
(5 M) did not influence the endogenous reverse-tran-
scription process (lane marked S), thus indicating the
specificity of PNAPBS for its target sequence.
In another set, we examined the efficacy of PNAPBS in
blocking the process of reverse transcription on purified
vRNA isolated from HIV-1 virions. The tRNA primer re-
mains bound to the viral genomic RNA upon isolation
and can be visualized in a tRNA-primer extension assay
upon addition of RT enzyme and dNTPs (Fig. 5B). Unlike
in the case of disrupted virion particles, tRNA extension
on the purified vRNA yielded a prominent 257-nt-long
tRNA–cDNA product (lane C). We established the identity
of this 257-nt-long tRNA–cDNA product by NaOH-medi-
ated degradation of the tRNA part, leaving a 181-nt cDNA
product (results not shown). Incubation with increasing
concentrations of PNAPBS in the reaction mixture resulted
in a corresponding decrease of the reverse transcription
product (lanes 1–8), thus indicating the efficacy of PNAPBS
in displacing the bound tRNA from its complementary
PBS sequence on the HIV-1 viral RNA and disrupting
reverse transcription. Further, the specificity of interac-
tion of PNAPBS in targeting its corresponding sequence
was indicated by the observation that scrambled PNA had
no effect on the reverse-transcription process (lane S).
Inhibition of HIV-1 replication in CEM cells by anti-
PBS PNA
Since anti-PBS PNA inhibited the reverse-transcription
process in the disrupted virions, we investigated their
efficacy in HIV-1-infected cell cultures. T cell lympho-
cytes, infected with the pseudotyped HIV-1 virus carrying
the firefly luciferase reporter, were transfected with vary-
ing concentrations of the individual anti-PBS PNA or
scrambled PNA. Cell extracts were then normalized for
the total protein and analyzed for quantitative levels of
luciferase expression to evaluate the effect of varying
concentrations of PNAPBS on HIV-1 production in these
cells. Luciferase activity obtained in the infected T cells
in the absence of PNA was arbitrarily set at 100% and
that obtained in the presence of PNA was calculated
relative to this value. These results presented in Fig. 6
represent the percentage luciferase activity at indicated
concentrations of PNAPBS in CEM (Fig. 6A) and Jurkat
cells (Fig. 6B). Substantial inhibition in virus production
as indicated by a corresponding decrease in the lucif-
erase activity was seen in both the T cell types. The
extent of inhibition directly correlated with the concen-
trations of PNAPBS. At 0.5 g PNAPBS concentration, a
modest inhibition of approximately 12–14% was obtained,
which increased to 54–58% inhibition at 1 g PNAPBS. A
near abolishment of virus production (approximately
1–2% luciferase activity) was obtained at 10 g of
PNAPBS. By contrast, scrambled PNA at similar concen-
tration exhibited no inhibition of virus production, thus
indicating the specificity of PNAPBS-mediated inhibition.
These results clearly demonstrate the antiviral efficacy of
PNAPBS.
Mechanism of PNAPBS-mediated inhibition of virus
production
A substantial reduction in the expression of the lucif-
erase reporter in both the CEM and the Jurkat cells
suggested inhibition of transcription of the HIV-1 mRNA.
FIG. 4. Effect of PNAPBS on tRNA3
Lys-primer extension assay. The tRNA3
Lys-primer was annealed to U5 PBS RNA and incubated in the absence or
presence of varying concentrations of PNAPBS or PNASCB (A). In another set U5 PBS RNA was preincubated in the absence or presence of varying
concentrations of PNAPBS or PNASCB followed by priming with tRNA3
Lys (B). Reverse transcription was initiated by the addition of HIV-1 RT, dNTPs, and
Mg2. The reaction products were resolved on a denaturing polyacrylamide–urea gel and analyzed on a phosphorImager. Lane 1, control without PNA;
Lanes 2 through 7 show the reverse transcription products in the presence of PNAPBS at 2.5, 5.0, 7.0, 8.0, 9.0, and 10.0 molar ratios of PNAPBS to TP,
respectively. Lanes 8 through 10 represent the reactions carried out in the presence of PNASCB at 2.5, 7.0, and 10.0 molar ratio of PNASCB to TP,
respectively. The tRNA3
Lys-derived () sssDNA product corresponded to the predicted size of 257 nucleotides. The position of the molecular markers
is indicated to the right.
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It is possible that the decreased transcription (results not
shown) may be due to lower levels of integrated HIV-1
cDNA into host cell genome. A decrease in cDNA syn-
thesis would be a direct consequence of PNAPBS inter-
ference in the reverse-transcription process as observed
in tRNA primer extension analysis in vitro (Fig. 4), as well
as in disrupted HIV-1 virions (Fig. 5A). We therefore
analyzed the amounts of integrated HIV-1 cDNA in the
host cell genome. For this, molar excess of oligomeric
PBS primer was primed with 1 g of total DNA isolated
from the PNAPBS transfected, infected T cell lymphocytes.
The annealed PBS primer was extended using radiola-
beled nucleotides and HIV-1 RT and products were re-
solved on an agarose gel and analyzed by phosphorim-
aging. The results are presented in Fig. 7. Extension of
the annealed PBS primer on the integrated viral DNA in
the host DNA resulted in a prominent product corre-
sponding to approximately 2–2.5 kb in size (lanes 2–9). A
complete absence of product in the uninfected cells
(lane 1) established the identity of this 2- to 2.5-kb prod-
uct as a result of PBS primer extension after annealing
specifically to its complementary sequence on the inte-
grated viral DNA. The intensity of this product decreased
quantitatively with increasing PNAPBS concentrations
(lanes 3–8) in both CEM and Jurkat cells, thus indicating
that the population of viral DNA present in total DNA
decreased with increasing PBS concentration. Interest-
ingly, scrambled PNA did not affect the amount of prod-
uct synthesis (lane 9). These results indicate that the
mechanism of PNAPBS inhibition may be directly related
to interference at the step of reverse transcription.
DISCUSSION
During the assembly of the HIV-1 virions, several cel-
lular tRNAs including tRNA3
Lys are packaged into the
FIG. 6. PNAPBS inhibits HIV-1 replication in T cells. T cell lymphocytes
infected with the pseudotyped HIV-1 virus expressing the firefly lucif-
erase reporter were transfected with indicated amounts of PNAPBS or
nonspecific scrambled PNA (PNASCB). The effect of PNAPBS on HIV-1
replication was monitored by analyzing the expression of firefly lucif-
erase in the cell extracts, at 48 h posttransfection. Firefly luciferase
activity was normalized to the total protein in the cell extract. Luciferase
activity obtained with HIV-1-infected CEM or Jurkat cells, transfected
with PNAPBS at indicated concentrations, are shown in A and B, respec-
tively. The amounts of PNASCB transfected corresponds to 10 g. Lucif-
erase expression obtained in the absence of PNA in the mock-trans-
fected HIV-1 infected T cells was arbitrarily set at 100% and luciferase
expression in the presence of PNA was calculated relative to this value.
The values shown are an average of three sets of experiments. The bar
represents standard deviation.
FIG. 5. PNAPBS-mediated inhibition of reverse transcription in dis-
rupted HIV-1 virions (A) and purified vRNA-tRNA (B). To examine the
efficacy of PNAPBS in invading the tRNA3
Lys primed duplex region and
blocking the process of reverse transcription, varying concentrations of
PNAPBS or PNASCB were incubated with disrupted HIV-1 virions contain-
ing the endogenous tRNA3
Lys-primed viral RNA genome, reverse tran-
scriptase and other viral proteins (A) or with purified viral RNA asso-
ciated tRNA (B). Reverse transcription in the disrupted virions was
carried out by endogenous RT upon supplementation with dNTP-Mg2.
A similar set of reactions was carried out in the case of the isolated
HIV-1 RNA–tRNA incubation mix, except that extraneous HIV-1 RT was
included in the assay. The reaction products were resolved on a
denaturing polyacrylamide–urea gel and analyzed by phosphorImag-
ing. Lane C represents reverse transcription products obtained in the
absence of PNA; Lanes 1 through 8 represent reactions carried out at
PNAPBS concentrations of 25 nM, 50 nM, 100 nM, 250 nM, 500 nM, 750
nM, 1 M, and 5 M, respectively. Lane S represents reverse tran-
scription product obtained in the presence of 5 M PNASCB. Position of
the molecular markers is shown in the lane marked M. The () ssDNA
product obtained with the isolated vRNA–tRNA complex corresponded
to the expected size of 257 nucleotides. This product, in the case of the
disrupted virions, was larger than 257 nucleotides, possibly represent-
ing products obtained due to strand transfer reaction.
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virion particles, but HIV-1 utilizes only tRNA3
Lys for the
initiation of reverse transcription (Jiang et al., 1993). The
tRNA3
Lys primes to the PBS, an 18-nucleotide sequence
which is located downstream of the U5 region of the 5
LTR and spans from nucleotides 183–201 of the viral RNA
genome. The 3-terminal 18 nucleotides of the primer
tRNA3
Lys are complementary to the PBS region (Ratner et
al., 1985). HIV-1 mutants that use reverse-transcription
primers other than the natural tRNA3
Lys exhibit reduced
replication efficiencies and revert to the wild-exhibit-type
tRNA3
Lys sequence upon prolonged culturing (Das et al.,
1995). Apart from the interaction of tRNA3
Lys with the PBS,
the A-loop region located upstream of the PBS has been
implicated in the selection and stabilization of tRNA3
Lys on
the viral genome (Li et al., 1997). This suggests the
importance of the primer-binding sequence as well as
the A-loop sequence during viral replication.
In the present study, we demonstrate the potential of
PNA complementary to the 5 nucleotides of the PBS and
11 nucleotides of the A-loop region (PNAPBS) to inhibit
virus replication in cell culture. PNAPBS stoichiometrically
binds to the PBS/A-loop region of the U5 PBS RNA (Fig.
2) and efficiently displaces the bound tRNA3
Lys primer (Fig.
3A). By contrast, scrambled PNA (Fig. 3B) as well as an
oligonucleotide having identical sequence as PNAPBS (re-
sults not shown) were unable to disrupt the preformed
(tRNA3
Lys-U5 PBS RNA) complex. This suggests that un-
like an oligonucleotide, the uncharged PNAPBS is able to
invade the duplex region of tRNA3
Lys-primed viral RNA
genome and disrupt this interaction. Our findings that the
binding of HIV-1 RT to the tRNA3
Lys alone is not affected by
PNAPBS, further suggesting that the affinity of PNAPBS is
highly specific toward its target sequence on the viral
genome (Fig. 3A, lanes 9 and 10).
It is possible that sequestering of the PBS region of the
viral genome by the complementary PNAPBS may have a
strong destabilization effect on the formation of enzyme-
tRNA3
Lys–viral RNA ternary complex. This interaction may,
in turn, prevent initiation of HIV-1 reverse transcription
and transition of the initiated primer to elongation. We
therefore investigated in vitro the effect of PNAPBS on the
natural tRNA3
Lys-primed initiation of reverse transcription
catalyzed by HIV-1 RT. In the absence of PNAPBS or with
scrambled PNA, the tRNA3
Lys-derived reverse transcrip-
tion yielded a full-length ()-strand strong stop DNA
product of predicted size (257 nucleotides). Incubation of
PNAPBS with U5 PBS RNA preprimed with tRNA3
Lys re-
sulted in significant reduction in the initiation of reverse
transcription and its subsequent elongation (Fig. 4A;
lanes 2–7). This suggests the ability of PNAPBS in desta-
bilizing the tRNA3
Lys primer by invading the duplex region
of the viral RNA. The inhibitory effect of PNAPBS was more
pronounced when incubated with unprimed U5 PBS RNA
(Fig. 4B; lanes 2–7), suggesting that PNAPBS once bound
to its target can effectively interfere with the priming
process.
It was therefore interesting to determine whether
PNAPBS could inhibit the process of reverse transcription
in the disrupted virions containing the endogenous
tRNA3
Lys-primed viral RNA genome and other viral com-
ponents/proteins. Our results indicate that incubation of
the disrupted virions with PNAPBS distinctly inhibited the
reverse-transcription process as a function of PNAPBS
concentration (Fig. 5A; lanes 1–8), thus indicating the
ability of PNAPBS to sequester its target in the disrupted
virions. Interestingly, purified vRNA–tRNA complex iso-
lated from HIV-1 virions yielded the characteristic 257-
nucleotide product (Fig. 5B, lane C), while the disrupted
virions yielded products longer than 257 nucleotides
(Fig. 5A). This suggests that the longer products with the
disrupted virions may have arisen as a result of strand
transfer.
These results imply that interaction of PNAPBS with the
PBS sequences on the viral genome blocks the base-
pairing interaction between PBS and the 3 terminal 5
nucleotides of tRNA3
Lys, resulting in destabilization of the
FIG. 7. Quantitation of integrated HIV-1 cDNA. HIV-1 cDNA popula-
tion integrated into the host genomic DNA was estimated from total
DNA isolated from HIV-1-infected T cell lymphocytes, transfected with
varying amounts of PNAPBS or PNASCB. One microgram of total DNA was
hybridized with the 17-mer PBS primer, complementary to the primer
binding sequence (nucleotides 183–201 of the HIV-1 genomic RNA) and
extended with HIV-1 RT in the presence of dNTPs and Mg2. The
products were resolved on agarose gel; the gel was dried and analyzed
on a phosphorImager. A representative figure of one such analysis is
presented. Lane 1 shows absence of product in uninfected cells. Lanes
2 through 8 represent DNA products obtained at 0, 0.5, 1.0, 2.5, 5.0, 7.5,
and 10 g of PNAPBS concentration. Lane 9 exhibits similar intensity of
product in PNASCB-transfected CEM or Jurkat cells. The size of this
product is approximately 2–2.5 kb. The position of the lambda HindIII-
digested markers in indicated on the right. The intensity of the product
obtained was quantified using ImageQuant software (Molecular Dy-
namics). The value obtained in the absence of PNA (Lane 2) was
arbitrarily set at 100% and that obtained in the presence of PNA was
calculated relative to this value. These values are indicated at the
bottom of each lane.
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tRNA3
Lys primer on the viral genome. Modification from
SUU to the suppressor anticodon CUA in the anticodon
of tRNA3
Lys also destabilizes the interaction between in
vivo packaged tRNA3
Lys and the viral RNA genome (Huang
et al., 1996). The inability of in vivo packaged mutant
tRNA3
Lys (CUU) to prime reverse transcription was sug-
gested to be a consequence of its inability to interact
with this A-rich loop of the viral genome. HIV-1 containing
the PBS complementary to tRNAHis rather than tRNA3
Lys
quickly reverts to the original PBS sequence comple-
mentary to tRNA3
Lys. However, when the A-loop was
changed such that it was complementary to the tRNAHis
anticodon, the tRNAHis became stabilized in the viral
population (Wakefield et al., 1996). It is thus obvious that
integrity of both the PBS region and the A-loop structure
is essential for viral infectivity.
Interestingly, all the natural occurring HIV-1 strains
isolated to date from clinical samples harbor the PBS
complementary to the tRNA3
Lys. Our results indicate that
PNAPBS can inhibit HIV-1 replication in cell culture (Fig. 6).
Our observation, that the amounts of proviral DNA inte-
grated in the host DNA decrease at increasing PNAPBS
concentration (Fig. 7), strongly suggest that the mecha-
nism of PNAPBS-mediated interference may be regulated
at the level of reverse transcription, though we cannot
rule out its ability to interfere at the step of transcription
directly by sequestering the PBS sequence of the nas-
cent RNA (results not shown).
The efficacy of PNA oligomers over conventional DNA
or RNA antisense oligonucleotides may be attributed to a
number of factors. PNA exhibit high affinity and specific-
ity for their complementary DNA and RNA sequences
(Eghlom et al., 1993), unlike oligonucleotides, which are
often confounded by nonspecific interactions (Stein,
1999). Moreover, PNA exhibit an added advantage in that
they can invade the duplex DNA/RNA by invasion or
displacement of one of the DNA strands and bind to their
target site (Lee et al., 1997; Peffer et al., 1993; Mollegaard
et al., 1994). These molecules are also chemically stable
and resistant to cleavage by nucleases and proteases
(Demidov et al., 1994).
It has been shown that PNA targeted to the coding
region of the Ha-ras mRNA effectively blocked the for-
mation of the translation initiation complex and polypep-
tide chain elongation (Dias et al., 1999). Likewise, PNA
targeted to the telomerase RNA blocked its activity, re-
sulting in progressive telomere shortening and causing
immortal human breast epithelial cells to undergo apo-
ptosis (Shammas et al., 1999; Hamilton et al., 1999).
Removal of antitelomerase PNA from the cell culture
restored the telomere length (Herbert et al., 1999). The
Bcl-2 protein synthesis in cell-free system was effectively
blocked by PNA targeted to AUG start codon and 5 UTR
of human B cell lymphoma (Bcl)-2 gene (Molongi et al.,
1999). A significant inhibition of the antinociceptive and
locomotor response to the delta opoid receptor agonists
was noted upon repeated i.c.v. administration of PNA
targeted to a region of the rat delta opoid receptor
(Fraser et al., 2000).
Recently, several studies involving PNA conjugated to
certain transporter peptides have been shown to be
efficiently taken up by the cells and to exhibit antisense
activity on the targeted gene (Chinnery et al., 2000; Ka-
magai et al., 2000; Ljungstrom et al., 1999; Branden et al.,
1999; Harrison et al., 1999; Scarfi et al., 1999; Aldrian-
Herrada et al., 1998; Pooga et al., 1998). The current
focus of our studies is to improve the biodelivery of
PNAPBS in the cells by conjugating it with membrane-
transducing peptides (MTD). Using this approach, we
have recently demonstrated the uptake efficiency and
antiviral efficacy of anti-TAR PNA conjugated with trans-
portan MTD vector (Kaushik et al., 2002). Studies are
underway to address the biodelivery and antiviral effi-
cacy of PNAPBS conjugated with various MTD vectors.
MATERIALS AND METHODS
DNA modifying enzymes were purchased from Roche
Molecular Biochemicals. HPLC-purified human placental
tRNA3
Lys was obtained from BIO S&T (Canada). Total DNA
isolation kit (Qiamp DNA kit) was a product of Qiagen
Inc. Cell culture media, fetal bovine serum (FBS), and
transfection reagents were either from Life Technologies
or Roche Molecular Biochemicals. Luciferase assay kit
was from Promega. Tritiated dNTPs, -32P-ATP, and -32P-
dNTPs were the products of Perkin–Elmer Life Sciences.
Pore-size filters measuring 0.45 m were from Schlei-
cher & Schuell. ELISA p24 antigen kit was from Abbott
Laboratories. DNA oligomers were synthesized at the
Molecular Resource Facility at UMDNJ. Polyamide nu-
cleic acid oligomers were synthesized at Applied Biosys-
tems Inc. All other reagents were of the highest available
purity grade and purchased from Fisher.
Plasmid and clones
The wild-type homodimeric (p66/p66) HIV-1 RT was
purified using the expression vector, pKK-RT66, con-
structed in this laboratory (Lee et al., 1997). An HIV-RNA
expression clone pHIV-PBS was a generous gift from Dr.
M. A. Wainberg (Arts et al., 1994). This clone contains a
947-bp fragment (473 to 1420) of pHHXB2 HIV-1
proviral clone and was used to generate RNA transcript
corresponding to the U5 PBS region. Another HIV-1 RNA
expression clone, pU5-PBS constructed in this laboratory
(Kaushik et al., 2001), was used to transcribe shorter
HIV-1 RNA (200 nucleotide) for gel-shift analysis. This
clone contains a 183-bp fragment corresponding to nu-
cleotides 473–656 of pHHXB2 HIV-1 proviral clone com-
prising PBS, U5, and part of the R region. An additional 17
nucleotides flanking the 5 terminus are derived from the
plasmid vector. The plasmid, pVSV-G, encoding the ve-
sicular stomatitis virus protein G under the control of the
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CMV immediate-early promoter was purchased from BD
Biosciences Clontech. The plasmid, pHIV-1JR-CSF-lucenv(),
was a kind gift from Dr. Planelles (Planelles et al., 1995).
This replication-defective HIV-1 clone lacks the envelope
gene and has a firefly luciferase reporter cloned in place
of nef in the HIV-1JR-CSFenv() cassette.
Isolation of p66/51 HIV-1 RT
The recombinant clone pKK-RT66 encoding the wild-
type p66 HIV-1 RT was expressed in JM109 and purified
as described before (Lee et al., 1997). To generate the
heterodimeric HIV-1 RT (p66/p51), the homodimeric en-
zyme (p66/p66) was subjected to proteolytic cleavage by
HIV-1 protease as follows: The p66/p66 species of HIV-1
RT was incubated with HIV-1 protease at 1:1 molar ratio
in a buffer containing 0.1 M potassium phosphate, pH 7.5,
1.0 M NaCl, 1 mM DTT, and 1 mM EDTA. Following 16 h
incubation at 4°C, the extent of proteolytic cleavage was
monitored by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) followed by Coomassie
blue staining. The heterodimeric enzyme was isolated on
a phosphocellulose column (Lee et al., 1997) and the
final enzyme preparation was stored at70°C in a buffer
containing 50 mM Tris–HCl pH 7.5, 100 mM NaCl, 1 mM
DTT, and 50% glycerol. Protein concentrations were de-
termined by using the Bio-Rad colorimetric kit as well as
by spectrophotometric measurements using E´280 
2.62  105 M1 cm1 for p66/51 heterodimer.
Preparation of 32P-labeled U5 PBS RNA template
The plasmid pU5-PBS was used to transcribe labeled
RNA for assessing the binding affinity of PNAPBS to its
target sequence on the HIV-1 genomic RNA, as de-
scribed previously (Kaushik et al., 2001). Briefly, the plas-
mid was linearized with the restriction enzyme Xho1 and
internally labeled with -32P-UTP (3000 Ci/mmol; Amer-
sham Life Sciences) using T7 RNA polymerase (Roche
Molecular Biochemicals). The plasmid was digested with
DNase I free of RNase and the labeled transcript was
extracted with phenol-chloroform and alcohol precipi-
tated. The RNA product was dissolved in DEPC-treated
water containing 10 mM DTT, further purified by G-50
spin column, and stored at 70°C.
Gel retardation assay
The 32P-labeled U5 PBS RNA (5  103 Cerenkov cpm)
was incubated with PNAPBS or scrambled PNA at varying
molar ratios for 3 h at 37°C in a binding buffer containing
50 mM Tris–HCl, pH 7.8, 60 mM KCl, 5 mM MgCl2, 10 mM
DTT, 10% glycerol, 0.01% bovine serum albumin, 0.01%
NP-40, and 500 ng of poly[r(I-C)], in a final volume of 15
l. Three microliters of RNA gel-loading dye (0.27%
bromphenol blue and 20% glycerol) was added to the
samples and subjected to non-denaturing gel analysis
on a 8% polyacrylamide gel in Tris–borate–EDTA (TBE)
buffer, pH 8.2. The gels were routinely prerun at 100 V for
30 min at 4°C in TBE buffer. The (U5 PBS RNA–PNA)
complexes were resolved at a constant voltage of 150 V
at 4°C. The gel was dried and analyzed on a phospho-
rimager (Molecular Dynamics). The percentage of la-
beled U5 PBS RNA retarded as a result of PNA binding
was quantified by Image-Quant.
Labeling of tRNA3
Lys
The HPLC purified human placental tRNA3
Lys obtained
from BIO S&T was 3 end-labeled with [32P]pCp by T4
RNA ligase (Ausubel et al., 1998). The labeled product
was extracted three times with phenol chloroform, pre-
cipitated with alcohol, lyophilized, and suspended in TE
buffer. This was further purified on a NAP-10 column to
remove the unincorporated radiolabeled nucleotides.
Preparation of R-U5-PBS HIV-1 RNA template
The plasmid, pHIV-PBS, was used to transcribe the
495-base-long U5-PBS RNA template as described ear-
lier (Arts et al., 1994). Briefly, the plasmid pHIV-PBS was
linearized with the restriction enzyme Acc1 and tran-
scribed using T7 RNA polymerase and other reaction
components from Roche Biochemicals. After in vitro tran-
scription reaction, the DNA template was removed by
DNase I digestion, followed by phenol-chloroform extrac-
tion and alcohol precipitation. The RNA products were
dissolved in DEPC-treated water containing 10 mM DTT,
further purified by G-50 spin column, and stored at
70°C.
Effect of PNAPBS on the formation of (tRNA3
Lys-U5 PBS
RNA) complex
U5 PBS RNA was preprimed with labeled tRNA3
Lys
(7.5  103 Cerenkov cpm) and incubated at 37°C for 2 h
with PNAPBS or scrambled PNA at varying molar ratios of
PNAPBS to U5 PBS RNA. The incubation buffer contained
50 mM Tris–HCl, pH 7.8, 10 mM DTT, 0.01% BSA, 60 mM
KCl, and 5 mM MgCl2. In another set, U5 PBS RNA was
preincubated with PNAPBS or scrambled PNA at 37°C for
1 h and then supplemented with the labeled tRNA3
Lys and
further incubated for 2 h. In a separate set, 1 M HIV-1
RT was incubated with labeled tRNA3
Lys (7.5  103 Cer-
enkov cpm) in the absence or presence of PNAPBS or
scrambled PNA. Three microliters of RNA gel loading
dye was added to 15 L of the reaction mixture. The
(U5-PBS RNA–tRNA3
Lys) complex formed was resolved by
electrophoresis on a 6% non-denaturing polyacrylamide
gel at 150 V in TBE buffer. The gels were dried and
analyzed on a phosphorimager.
Reverse transcription of U5-PBS RNA template
primed with natural tRNA3
Lys
U5 PBS RNA was annealed with the natural tRNA3
Lys at
2:1 molar ratio. Reverse-transcription reactions were car-
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ried out by incubating 5 nM of U5 PBS RNA/tRNA3
Lys
template primer with 50 nM HIV-1 RT, in a reaction
mixture containing 50 mM Tris–HCl, pH 7.8, 10 mM DTT,
100 g/mL BSA, 5 mM MgCl2, and 50 M each of dATP,
dTTP, dGTP, and 2 M of -32P-dCTP (0.5 Ci/pmol).
Reactions were initiated by the addition of enzyme and
terminated by the addition of 20 mM EDTA. The samples
were extracted with phenol-chloroform, precipitated with
alcohol, and lyophilized. Ten microliters of 1 Sanger’s
gel loading solution was added to the samples (Sanger
et al., 1977) and the products were resolved on an 8%
polyacrylamide–urea gel.
The effect of PNAPBS on in vitro natural tRNA3
Lys-primed
reverse transcription was assessed as follows. In one
set, varying molar ratios of PNAPBS or scrambled PNA
was incubated with U5 PBS-RNA template preprimed
with the tRNA3
Lys at 37°C for 2 h. In another set, PNAPBS or
scrambled PNA was first incubated with U5 PBS–RNA
template at 37°C for 2 h, followed by priming with
tRNA3
Lys. Reverse transcription on both these sets was
assessed as described above.
Cell culture and transfection
CEM and Jurkat T cell lymphocytes were cultured in
RPMI 1640 medium supplemented with 10% fetal calf
serum, 4 mM L-glutamine, 100 U/ml of penicillin, and 100
g/ml of streptomycin at 37°C and 5% CO2. The chroni-
cally HIV-1-infected H9 cells (H9Lai) were maintained un-
der identical conditions except that they were supple-
mented with 20% fetal calf serum. Human 293T cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM), supplemented with 10% fetal bovine serum and
1% penicillin–streptomycin. For transfection in CEM, the
cells were grown to mid-log phase, washed with phos-
phate-buffered saline without Ca2 or Mg2, resus-
pended in RPMI-1640 medium (5.0  106 cells in 250 l),
and electroporated at 250 V/900 microfarad capacitance
using the Bio-Rad Gene pulsar II. Jurkat and 293T cells
were transfected in accordance with the manufacturer’s
protocol using the X-tremeGENE Q2 Transfection re-
agent (Roche Molecular Biochemicals) or the calcium-
phosphate transfection system (Life Technologies), re-
spectively.
Isolation of HIV-1 virions
H9LAI cells were used as the source of the HIV-1 virus.
These chronically HIV-1-infected cells were extensively
washed to remove previously produced virions, sus-
pended in 25 ml of RPMI 1640 complete medium at a cell
density of 104 cells/ml, and grown for 3 days in a 37°C
incubator. The culture medium was centrifuged at 1200
rpm for 7 min to remove cells. An aliquot of the cell
supernatant was used for p24 antigen estimation. The
virus-containing supernatant was filtered through a
0.45-m pore-size filter (Schleicher & Schuell), and the
virions were pelleted by centrifugation at 28,000 rpm for
45 min in a Beckman SW28 rotor. The HIV-1 virion pellet
was disrupted in 300 l buffer containing 50 mM Tris–
HCl, pH 7.8, 100 mM KCl, 0.5 mM EDTA, and 0.2% NP-40
and used as a source of tRNA3
Lys-primed HIV-1 viral RNA
genome, endogenous RT, and other packaged viral com-
ponents.
Isolation of HIV-1 vRNA
HIV-1 virions isolated from H9LAI cells as described
above were used as a source for extracting the virion
RNA. The virions were resuspended in 500 l of buffer
containing 50 mM Tris–HCl (pH 7.8), 100 mM NaCl, 2.5
mM EDTA, 1.0% SDS, and 300 g of proteinase K and
incubated at 37°C for 30 min, followed by 3 extraction
with phenol-chloroform-isoamyl alcohol (25:24:1). RNA
was precipitated in 0.3 M Na-acetate (pH 5.2) and 70%
ethanol at 80°C, centrifuged at 16,000 g for 30 min,
washed with 70% ethanol, and air dried. Contaminating
DNA was removed by digestion with DNase I (RNase-
free; Roche Biochemicals) as per the supplier’s instruc-
tions. RNA was reextracted with phenol-chloroform-
isoamyl alcohol (25:24:1), precipitated with 0.3 M Na
acetate and 70% ethanol, and pelleted at 16,000 g for 30
min. Following 70% ethanol washing, the air-dried RNA
pellet was resuspended in 100 l of 25 mM Tris–HCl, pH
7.8/0.5 mM EDTA, and stored at 20°C.
Endogenous reverse transcription in the disrupted
HIV-1 virions and tRNA-primer extensions on
associated viral RNA in the presence of PNAPBS
The effect of PNAPBS on endogenous reverse transcrip-
tion in the disrupted HIV-1 virions as well as on viral
RNA-associated tRNA was assessed as follows: Dis-
rupted HIV-1 virions (10 l) were incubated at 4°C for 3 h
and subsequently at 37°C for 30 min, in the presence or
absence of varying concentrations of PNAPBS or scram-
bled PNA in a 15 l volume. The components of the
incubation mix were 50 mM Tris–HCl, pH 7.8, 10 mM DTT,
66 mM KCl, 0.3 mM EDTA, 0.14% NP-40, and 1 U/l
RNasin. Reverse transcription was initiated by the addi-
tion of 5 l of 4 RT buffer (40 mM MgCl2, 40 mM
dithiothreitol, 200 mM KCl, 120 g of actinomycin D/ml,
100 g BSA/mL, 40 M each of dATP, dGTP, dTTP, 4 M
dCTP), and 5 Ci of -32P-dCTP (3000 Ci/mmol). The
labeled cDNA product generated at 37°C for 5 min was
further chased for 30 min by the addition of 1 l de-
oxynucleoside triphosphate (dNTP) mix (10 mM each
dNTP) and the reaction was quenched with 50 mM EDTA.
Following phenol–chloroform extraction and alcohol pre-
cipitation, the pellet was resuspended in formamide
loading buffer, heated at 90°C for 5 min, resolved on a
denaturing 6% polyacrylamide–urea gel, and analyzed by
phosphorimaging.
In another set, similar reactions were carried out with
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the isolated HIV-1 RNA-tRNA3
Lys, except that 5 l of puri-
fied HIV-1 RNA-tRNA was used per reaction and 150 ng
of recombinant HIV-1 RT was included in the assay.
T cell infections
Pseudotyped HIV-1 virion stocks were produced by
cotransfection of pHIV-1JR-CSF-lucenv() (Planelles et al.,
1995) and pVSV-G (BD Biosciences Clontech) in 293T
cells. Culture medium was harvested at 24, 48, and 72 h
posttransfection; an aliquot was removed for p24 antigen
quantification using the ELISA p24 antigen kit (Abbott
Laboratories), and the virus stock was frozen at 80°C.
To determine the effect of PNAPBS on HIV-1 production in
T cells, CEM and Jurkat cells (5  106 cells) were in-
fected at 37°C for 1 h with the pseudotyped HIV-1 virions
in the presence of 10 g/ml of polybrene to achieve
multiplicities of infection (m.o.i.) of 10. The cells were
extensively washed with PBS to remove the viruses,
resuspended in 5.0 ml of complete RPMI medium, and
incubated for another 1 h at 37°C. The infected T cells
were then transfected in the presence or absence of
varying amounts of the individual PNAPBS or scrambled
PNA and grown in 10 ml of complete RPMI media. Forty-
eight hours posttransfection, the cells were harvested
and analyzed for firefly luciferase reporter and HIV-1
cDNA levels as described below.
Luciferase assay
Luciferase assays were performed as per the Pro-
mega’s luciferase assay protocol. Forty-eight hours post-
transfection, the cells were washed with PBS and lysed
in 100 l of the reporter lysis buffer (Promega). The cell
extracts were normalized for total protein (Bio-Rad) and
assayed for firefly luciferase activity in a 96-well fluorot-
rac plate using a Packard Top Count Luminescence
Counter. The results of at least three separate transfec-
tions were analyzed for each experiment.
Total DNA isolation and estimation of integrated HIV-
1 cDNA
To estimate the HIV-1 cDNA integrated into the host
cell chromosome, total DNA was isolated from the trans-
fected T cells using the Qiamp DNA kit (Qiagen Inc.). A
17-mer PBS oligomer having sequence complementary
to the PBS region of the HIV-1 genomic RNA was used as
a probe for analyzing the amounts of HIV-1 cDNA inte-
grated into the host genomic DNA by oligomer extension
analysis. Hybridization of the probe to the HIV-1 cDNA
was achieved by incubating 1 g of total DNA with 50
pmol of 17-mer PBS oligomer in 1 annealing buffer (50
mM Tris–HCl, pH 7.8 and 50 mM KCl) at 75°C for 7 min
and allowing it to cool gradually to room temperature.
Extension reactions were carried out in a buffer contain-
ing 50 mM Tris–HCl, pH 7.8, 10 mM DTT, 60 mM KCl, 10
mM MgCl2, 100 g BSA/mL, 10 M each of dATP, dGTP,
dTTP, 1 M dCTP, 5 Ci of -32P-dCTP (3000 Ci/mmol)
and 200 ng of heterodimeric HIV-1 RT. The labeled cDNA
product generated at 37°C for 10 min was chased with
cold dNTP mix (500 M each) for an additional 45 min at
37°C and quenched with 50 mM EDTA. The cDNA prod-
uct was phenol-chloroform extracted, alcohol precipi-
tated, and the pellet resuspended in 15 l of 1 loading
buffer (10% glycerol and 0.01% each xylene cyanol and
bromphenol blue). The products were resolved on 0.8%
agarose gel; the gel was dried and subjected to phos-
phorimager analysis.
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